CD44 expression predicts disease outcome in localized large B cell lymphoma
暂无分享,去创建一个
J Hermans | S. Heisterkamp | J. Hermans | P. Kluin | J. V. Krieken | S. Pals | P. Drillenburg | P Drillenburg | VJM Wielenga | MHH Kramer | JHJM van Krieken | HC Kluin-Nelemans | S Heisterkamp | EM Noordijk | PM Kluin | ST Pals | M. Kramer | E. Noordijk | H. Kluin‐Nelemans | Vjm Wielenga
[1] B. Imhof,et al. Expression of integrins and CD44 isoforms in non‐Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high‐grade malignant lymphomas , 1994, The Journal of pathology.
[2] P. Kincade,et al. CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.
[3] D. Parker. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. , 1995, Lancet.
[4] K. Miyake,et al. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long- term bone marrow cultures , 1990, The Journal of experimental medicine.
[5] J. R. de los Toyos,et al. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells , 1987, The Journal of cell biology.
[6] D. Neuberg,et al. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. , 1998, Blood.
[7] C. Meijer,et al. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. , 1989, Blood.
[8] E. Puré,et al. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation , 1993, The Journal of experimental medicine.
[9] P. Herrlich,et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.
[10] B. Caillou,et al. CD44 contributes to T cell activation. , 1989, Journal of immunology.
[11] I. Stamenkovic,et al. Distinct effects of two CD44 isoforms on tumor growth in vivo , 1991, The Journal of experimental medicine.
[12] E. Manten-Horst,et al. Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. , 1997, Acta haematologica.
[13] R. Clark,et al. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma , 1996, The Journal of cell biology.
[14] M. Ladanyi,et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.
[15] F M van den Berg,et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.
[16] K. Offit,et al. BCL-6 in diffuse large-cell lymphomas. , 1996, Important advances in oncology.
[17] S. Jalkanen,et al. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. , 1990, Blood.
[18] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[19] Klaus Rajewsky,et al. Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.
[20] H. Degrendele,et al. Requirement for CD44 in activated T cell extravasation into an inflammatory site. , 1997, Science.
[21] Brian Seed,et al. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family , 1989, Cell.
[22] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[23] L. Picker,et al. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway , 1996, The Journal of experimental medicine.
[24] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[25] K. Heider,et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. , 1995, European journal of cancer.
[26] G. Salles,et al. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. , 1993, Blood.
[27] S. Jalkanen,et al. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man , 1986, European journal of immunology.
[28] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[29] R. Pieters,et al. Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. , 1990, Leukemia.
[30] E. Jaffe,et al. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. , 1990, Blood.
[31] I. Stamenkovic,et al. Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function , 1997, The Journal of experimental medicine.
[32] E. Noordijk,et al. Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non‐Hodgkin's lymphomas, according to data in the population‐based registry of the comprehensive cancer centre west , 1998, Cancer.
[33] W. Eisterer,et al. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. , 1995, Blood.
[34] K. Musshoff. Klinische Stadieneinteilung der Nicht-Hodgkin lymphome , 1977 .
[35] P. Herrlich,et al. CD44 variant exon epitopes in primary breast cancer and length of survival , 1995, The Lancet.
[36] E. Noordijk,et al. Gastric lymphomas compared with lymph node lymphomas in a population‐based registry differ in stage distribution and dissemination patterns but not in patient survival , 1997, Cancer.
[37] J. Bell,et al. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon , 1995, The Journal of cell biology.
[38] J Hermans,et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.
[39] Martin Hofmann,et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.
[40] J. Bell,et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[41] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[42] S. Jalkanen,et al. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. , 1991, The Journal of clinical investigation.
[43] C. Figdor,et al. Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. , 1990, Journal of immunology.
[44] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.
[45] C. Meijer,et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). , 1990, Leukemia.
[46] M. Shipp. Can we improve upon the International Index? , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] D. Jong,et al. Clinical Relevance of BCL 2 , BCL 6 , and MYC Rearrangements in Diffuse Large B-Cell Lymphoma , 1998 .